["Cost-effectiveness" of cervical screening].
"Cost-effectiveness" analyses at cervical cytological screening measure effectiveness in terms of the years of gained life. They have proved that screening does not reduce costs, but its effect is saving the live of women and improving their quality of life as well. For Bulgaria (2003) on the basis of EU data (2004) costs for a treatment of precancer and cancer of uterine cervix for a year are calculated as 67,500 Euro for CIS (225 cases, 300 Euro each), for 1st and 2nd stage--6,120,000 Euro (680 cases, each of 9000 Euro), for 3rd and 4th stage--11,430,000 Euro (381 cases, each of 30,000 Euro). This analysis shows that an annual investment of about 3 mill Euro in population cervical screening in Bulgaria will save a considerable amount of money spent by state for treatment mostly of advanced invasive forms of disease, which at the present level of incidence would cost about 17.6 mill Euro per annum complied with the European standards, i.e. 5 to 6 times less costs for a different periods of time.
Kostova
P
P
D000328:Adult; D000368:Aged; D002031:Bulgaria / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D005260:Female; D017048:Health Care Costs / Q000639:trends; D006801:Humans; D008403:Mass Screening; D008875:Middle Aged; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000191:economics / Q000453:epidemiology / Q000628:therapy; D014626:Vaginal Smears / Q000191:economics* / Q000706:statistics & numerical data